疫苗杂志：
Vaccine. 2010 Apr 27. [Epub ahead of print]
Intradermal hepatitis B vaccination in non-responders after topical
application of imiquimod (Aldara((R))).
Roukens AH, Vossen AC, Boland GJ, Verduyn W, van Dissel JT, Visser LG.
Department of Infectious Diseases, Leiden University Medical Center, The
Netherlands.
Abstract
Trial registration: NTR1043
<http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1043>. BACKGROUND:
Five to ten percent of immunocompetent persons fail to develop a protective
immune response to hepatitis B vaccination, and are defined non-responders
(NR). We investigated the immune response to intradermal hepatitis B
vaccination after pre-treatment of the skin with the TLR7 agonist imiquimod.
METHODS: Twenty-one non-responders (anti-HBs <10IU/l after at least 6
intramuscular hepatitis B vaccinations) were randomly assigned to the control
group (N=11) or the experimental group (N=10). Participants in both groups
received 3 intradermal (ID) vaccinations with 5mug HBsAg (0.125mL) at 0, 1 and
6 months. In the experimental group, the dermal site of injection was
pre-treated with 250mg imiquimod ointment. Anti-HBs antibodies were determined
at 0, 1, 2, 6 and 7 months. RESULTS: In both study groups, 70% of the
participants developed a protective immune response (anti-HBs>/=10IU/l), after
the 3rd intradermal vaccination. CONCLUSION: The application of imiquimod on
the skin prior to intradermal vaccination did not enhance the humoral response
to hepatitis B vaccine. However, irrespective of imiquimod application, 70% of
the NR who had not responded to 6 previous intramuscular vaccinations,
developed a protective immune response with high affinity antibodies after 3
ID hepatitis B vaccinations with 5mug HBsAg. Copyright © 2010. Published by
Elsevier Ltd.
PMID: 20433806 [PubMed - as supplied by publisher]
| 欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |